CHRISTIAN HANSEN Chr. Hansen Q4 2022/23
Investor presentation October 12, 2023
Safe harbor statement
This presentation contains forward-looking statements that reflect management's current views and expectations with respect to Chr. Hansen's future and potential financial performance.
Those forward-looking statements are based upon data and information currently available to the company, and on a variety of assumptions, many of which may be beyond our control and subject to risks and uncertainties that may cause the actual results of the Company or the industry to differ materially from such forward-looking statements.
The information, opinions and forward-looking statements are provided as of the date stated in this document and the Company is under no obligation to publish any updates thereof except for what is required by applicable law or stock exchange rules and regulations.
Strong Q4 supports a solid performance for the first twelve months of the extended financial year 2022/23
Financial highlights Q4/YTD 2022/23
ORGANIC REVENUE GROWTH
16%
YTD 2022/23: 11%
EBIT MARGIN
before special items
28.0% (0.1%-pt vs. LY)
YTD 2022/23: 26.9%
(0.1%-pt vs. LY)
FREE CASH FLOW
before acquisitions and special items
EUR 69m
YTD 2022/23: EUR 202m
3
Double-digit growth in lighthouses and core
Strategic and operational highlights Q4/YTD 2022/23
2025 STRATEGY
REINVEST | REINVEST | |
Successful customer collaborations | New probiotic strain introduced in | |
to drive productivity and accelerate | gut-brain in Human Health with | |
innovation in Dairy and plant-based | publication of its first clinical study | |
including introduction of live | ||
probiotics in ambient category |
LEVERAGE | GROUP |
Approval from the Chinese | Solid pricing contribution from |
authorities with regards to the | inflation-driven price increases |
technology to produce each of | |
three HMOs (2'-FL, LNT and 3-FL) |
ORGANIC GROWTH
Q4/YTD 2022/23 | |||
41% | |||
24% | |||
14% | 16% | ||
10% | 11% | ||
Core1 | Lighthouses1 | Group | |
Q4 22/23 | YTD 22/23 |
1 Core includes FC&E ex. Bioprotection and Fermented Plant Bases, Human Health and Animal Health. Lighthouses includes Bioprotection, Fermented Plant Bases, HMO and Plant Health.
4
Double-digit growth in both FC&E and H&N driven by volume and pricing
Organic sales performance by business area
GROUP
16% | ||||||||||||
6% | 9% | 14% | 9% | 6% | 10% | 11% | 9% | |||||
Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | ||||
21/22 | 22/23 |
FOOD CULTURES & ENZYMES | HEALTH & NUTRITION¹ |
16% | 16% |
10% | 7% | 7% | 6% | 5% | 8% | 12% | 10% | 13% | 26% | 13% | 6% | 12% | 9% | 7% | ||||||||||
-4% | ||||||||||||||||||||||||
Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |||||||
21/22 | 22/23 | 21/22 | 22/23 |
VOLUME/ | PRICE | FX | EUR | |
MIX | GROWTH | |||
Q4 | +9% | +7% | -9% | +7% |
YTD | +5% | +6% | -1% | +10% |
VOLUME/ | PRICE | FX | EUR | |
MIX | GROWTH | |||
Q4 | +6% | +10% | -10% | +6% |
YTD | +3% | +8% | -2% | +9% |
VOLUME/ | PRICE | FX | EUR | |
MIX | GROWTH | |||
Q4 | +14% | +2% | -6% | +10% |
YTD | +8% | +3% | 0% | +11% |
1 The acquisition of HSO HC is included in organic growth since Q3 2020/21 (closing April 2020), UAS Labs (closing July 2020) and Jennewein (closing October 2021) since Q1 2021/22.
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Chr. Hansen Holding A/S published this content on 11 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2023 07:04:08 UTC.
